PLx Pharma Winddown Temettü

Temettü kriter kontrolleri 0/6

PLx Pharma Winddown does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-8,713,333.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-8,713,333.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

Aug 12

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

May 10

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Nov 03

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Sep 23

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if PLXP.Q's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if PLXP.Q's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

PLx Pharma Winddown Piyasaya Karşı Temettü Getirisi

PLXP.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PLXP.Q)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Pharmaceuticals)	2.3%
Analist tahmini (PLXP.Q) (3 yıla kadar)	n/a

Önemli Temettü: Unable to evaluate PLXP.Q's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate PLXP.Q's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate PLXP.Q's payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as PLXP.Q has not reported any payouts.

PLx Pharma Winddown Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

PLx Pharma Winddown Corp. Files Form 15

Plx Pharma Winddown Corp. Announces Executive Changes

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC

PLx Pharma Inc. Announces Resignation of John W. Hadden II as Member of Board

PLx Pharma Inc. to Report Q3, 2022 Results on Nov 11, 2022

PLx Pharma Receives Written Notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

PLx Pharma Inc., Annual General Meeting, Nov 08, 2022

PLx Pharma Non-GAAP EPS of -$0.52 misses by $0.02, revenue of $0.48M

PLx Pharma Inc. to Report Q2, 2022 Results on Aug 12, 2022

Consensus forecasts updated

Is PLx Pharma (NASDAQ:PLXP) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$16.33

PLx Pharma Inc. to Report Q1, 2022 Results on May 13, 2022

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

Key Executive recently bought US$50k worth of stock

No longer forecast to breakeven

PLx Pharma Inc. to Report Q4, 2021 Results on Mar 11, 2022

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

PLx Pharma: First Commercial Launch Makes It Attractive

Consensus forecasts updated

PLx Pharma Inc.’s VAZALORE to Launch in Nearly 8,000 CVS Stores this Month

Consensus revenue estimates fall to US$5.73m

Price target increased to US$21.50

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Plx Pharma Inc.’s VAZALORE to Launch in over 4,500 Walmart Stores Nationwide in August

Executive Chairman recently bought US$100k worth of stock

PLx Pharma (NASDAQ:PLXP) Is In A Strong Position To Grow Its Business

Consensus forecasts updated

Consensus revenue estimates increase to US$6.80m

Earnings beat expectations

Executive Chairman recently bought US$200k worth of stock

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $63 million.

Have Insiders Been Buying PLx Pharma Inc. (NASDAQ:PLXP) Shares?

PLx Pharma Inc. has completed a Follow-on Equity Offering in the amount of $2.3 million.

PLx Pharma Receives FDA Approval of sNDAs for Both Vazalore 325 Mg and 81 Mg

New 90-day high: US$6.89

New 90-day high: US$6.50

PLx Pharma Inc. announced that it has received $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

PLx Pharma Inc. announced that it expects to receive $18.008598 million in funding from White Rock Capital Management, L.P., Level One Partners LLC and other investors

PLx Pharma EPS misses by $0.10

Earnings miss expectations

New 90-day high: US$4.31

PLx Pharma Inc. to Report Q3, 2020 Results on Nov 13, 2020

New 90-day high - US$4.18

PLx Pharma Inc. to Report Q2, 2020 Results on Aug 14, 2020

PLx Pharma Inc.(NasdaqCM:PLXP) dropped from Russell Microcap Value Index

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin